Condition: Major Depression Disorder · Sponsor: Yale University
This observational protocol is intended to provide long-term follow-up data on patients initiating or continuing treatment with either Spravato® or IV ketamine. This can provide us information on the patient acceptability and satisfaction, patterns of use, long-term effectiveness, and safety of the two approaches. This 5-year, 6-site study will enroll 450 total patients. The sites will comprise 3 academic medical centers and 3 community psychiatric practices.
This description comes directly from the study's public registry record.
Cindy Voghell · 203-737-4784 · cynthia.voghell@yale.edu
Always discuss trial participation with your own doctor first.
| Mood Institute | Milford, Connecticut, United States | Recruiting |
| Yale School of Medicine | New Haven, Connecticut, United States | Recruiting |
| Emory University | Atlanta, Georgia, United States | Recruiting |
| University of Michigan | Ann Arbor, Michigan, United States | Recruiting |
| LifeStance Health | Moore, Oklahoma, United States | Recruiting |
| Houston Center for Advanced Psychiatric Treatment | Bellaire, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06725277